Woodsmoke Exposure, Influenza Infection, and Nasal Immunity
Start Date
9/26/2025
Completion Date
12/31/2028
Summary
This study will investigate the effects of woodsmoke (WS) exposure on human nasal mucosal immune responses to viral infection. The study tests the hypotheses that WS exposure modifies biomarkers of nasal mucosal immune function, increases in Live Attenuated Influenza Virus (LAIV) -induced nasal symptoms, and reduces mucosal antibody production.
Detailed Description
This study will investigate the effects of woodsmoke (WS) exposure on human nasal mucosal immune responses to viral infection. The study tests the hypotheses that WS exposure modifies biomarkers of nasal mucosal immune function, increases LAIV-induced nasal symptoms, and reduces mucosal antibody production. Healthy volunteers will be randomized for a 2-hr exposure to WS or placebo (filtered air) and then inoculated with either live attenuated influenza virus (LAIV) or placebo. Nasal mucosal samples, symptoms, and peripheral blood will be collected on days 1,2,3,7, and 21 post-exposure/LAIV and assessed for a) mucosal antiviral responses using targeted and non-targeted analysis of the secretome and tissue-level gene expression; b) symptoms, virus quantity, differential cell count, and virus-specific antibody levels; and c) biomarker signatures associated with infection outcomes using computational modeling tools.
Eligibility Criteria
Age Range: 18 years to 49 years
Interventions
LAIV nasal vaccine is chosen as a model viral infection
Wood smoke
Placebo for LAIV nasal vaccine is chosen as a model viral infection
Placebo for Wood Smoke (clean Air Exposure)
Conditions
Locations
Mary Ellen Jones
Chapel Hill, North Carolina 27599
United States